Summit Therapeutics (SMMT) Return on Equity (2020 - 2025)
Summit Therapeutics filings provide 6 years of Return on Equity readings, the most recent being 0.0% for Q3 2025.
- Quarterly Return on Equity changed 0.0% to 0.0% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 0.0% through Sep 2025, changed 0.0% year-over-year, with the annual reading at 0.01% for FY2024, 5.0% up from the prior year.
- Return on Equity hit 0.0% in Q3 2025 for Summit Therapeutics, up from 0.0% in the prior quarter.
- Across five years, Return on Equity topped out at 0.0% in Q3 2025 and bottomed at 0.07% in Q4 2023.
- Average Return on Equity over 5 years is 0.02%, with a median of 0.01% recorded in 2021.
- The largest annual shift saw Return on Equity fell -6bps in 2023 before it grew 6bps in 2024.
- Summit Therapeutics' Return on Equity stood at 0.01% in 2021, then soared by 42bps to 0.01% in 2022, then crashed by -1141bps to 0.07% in 2023, then soared by 92bps to 0.01% in 2024, then surged by 49bps to 0.0% in 2025.
- Per Business Quant, the three most recent readings for SMMT's Return on Equity are 0.0% (Q3 2025), 0.0% (Q2 2025), and 0.01% (Q1 2025).